Curis, Inc. filed a Form S-3 registration statement with the SEC on November 13, 2026, covering the resale of up to 33,333,360 shares of common stock by selling stockholders who participated in an October 2026 private placement.

Key Highlights

  • Total shares registered: Up to 33,333,360 shares of Curis common stock are covered by the resale prospectus.
  • Three components: The shares consist of 2,574,517 shares of common stock, 14,092,163 shares issuable upon exercise of October 2026 Pre-Funded Warrants, and 16,666,680 shares issuable upon exercise of October 2026 Common Warrants.
  • Source transaction: The securities were sold to the selling stockholders in a private placement completed in October 2026, according to the filing.
  • No proceeds to company from resale: Curis disclosed it will not receive any proceeds from the sale of shares offered by the prospectus, though it will receive proceeds from any cash exercise of the October 2026 Warrants.
  • Stock price at filing: The last reported closing sale price of Curis common stock on Nasdaq was $0.5718 per share on November 12, 2026, as stated in the prospectus.
  • Company classification: Curis is identified in the filing as a non-accelerated filer and smaller reporting company.
  • Registration costs: Curis agreed, pursuant to a registration rights agreement with the selling stockholders, to bear all expenses incurred in connection with the registration of these shares.

Curis Files Resale Registration for October 2026 Private Placement Securities

Curis, Inc. (NASDAQ:CRIS), a Delaware-incorporated biopharmaceutical company headquartered at 128 Spring Street, Lexington, MA, filed a Form S-3 registration statement on November 13, 2026, to register up to 33,333,360 shares of its common stock for resale by selling stockholders. According to the filing, those shares originate from a private placement conducted in October 2026 and have not yet been registered for public resale.

The prospectus breaks the registered shares into three categories. The first consists of 2,574,517 shares of common stock with a par value of $0.01 per share. The second consists of 14,092,163 shares issuable upon exercise of what the filing calls the "October 2026 Pre-Funded Warrants." The third consists of 16,666,680 shares issuable upon exercise of the "October 2026 Common Warrants," which the filing notes may, in certain circumstances, be satisfied instead by pre-funded warrants. Together, the two warrant series are referred to in the filing as the "October 2026 Warrants."

The filing states that Curis will not receive proceeds from the resale of shares by the selling stockholders, but will receive proceeds to the extent any October 2026 Warrants are exercised for cash. The selling stockholders, described in the filing as including their donees, pledgees, transferees, or other successors-in-interest, may sell shares through ordinary brokerage transactions or other means described in the prospectus at fixed, market, related-market, varying, or negotiated prices. The registration statement was filed pursuant to Rule 415 for a delayed or continuous offering and remains subject to completion pending SEC effectiveness.

What Was Disclosed

Curis filed an S-3 registration statement on November 13, 2026, to enable selling stockholders from an October 2026 private placement to resell up to 33,333,360 shares of common stock, including shares underlying two series of warrants. Curis will bear registration expenses under a registration rights agreement.